Parkinson’s Vaccine Triggers Solid Immune Response, Phase 1 Clinical Trial Shows

Parkinson’s Vaccine Triggers Solid Immune Response, Phase 1 Clinical Trial Shows

AFFiRiS’s new Parkinson’s vaccine, AFFITOPE PD03A, triggered a solid immune response against the alpha-Synuclein (aSyn) protein associated with the disease, according to a Phase 1 clinical trial.

Patients also tolerated the therapy well, researchers said.

Werner Poewe, a professor at Austria’s Medical University Insbruck, presented the results at the 21stInternational Congress of Parkinson’s Disease and Movement Disorders in Vancouver, Canada, June 4-8.

He is part of a European collaboration known as SYMPATH whose aim is to develop vaccines targeting the aSyn protein. The collaboration involves AFFiRiS and seven academic and industry partners in Germany, France and Austria. The European Union is financing SYMPATH.

The 52-week Phase 1 trial (NCT02267434) evaluated the immune response, safety and tolerability of AFFITOPE PD03A in patients with early Parkinson’s disease.

Researchers randomized 36 patients to receive one of two doses of the vaccine or a placebo. One dose was five times larger than the other. The basic immunization was an injection a month for four months. At 36 weeks, patients received a booster immunization.

The vaccine triggered immune responses against the aSyn protein over time. The reactions were dose-dependent, meaning that the higher dose triggered a stronger response than the lower one. The booster immunization reactivated the vaccine’s antibody production, researchers said.

Both doses of the vaccine were well tolerated, with patients reporting no serious adverse events.

AFFITOPE PD03A is a synthetically produced aSyn-mimicking peptide — or protein component — that targets the aSyn protein.

ASyn plays a key role in the onset and progression of Parkinson’s. Current treatments can only alleviate the disease’s symptoms. Scientists say aSyn has the potential to actually slow the disease’s progression.

SYMPATH researchers hope to develop an aSyn-targeting vaccine for multiple system atrophy as well as Parkinson’s. The consortium has already created a vaccine besides AFFITOPE PD03A, known as AFFITOPE PD01A. A key reason the EU became involved in the project is that current therapies for many neurodegenerative conditions are unable to alter the diseases’ course.

“The immunogenicity profile [of AFFITOPE PD03A] looks encouraging and supports the hypothesis that patients elicit an antibody response specific to alpha synuclein, a protein that is believed to be contributing to the pathogenesis of Parkinson’s,” Poewe, the principal investigator of the study, said in a press release.

8 comments

    • Ali says:

      Hi Peet,

      My father was also diagnosed with MSA and sadly passed away could you tell me how is the diabetes pill working and which one are you taking ? There are many other people I know suffering from this horrible disease as well.

      Best Regards

  1. Raul sosa says:

    I will like to participate in the vaccine trial to clear the alpha sinucleion. Im 59 yrs Available 24/7. Im taking sinemet 25/100. Diagnose on 2016 with parkinson. Phone 787 674 7280.l live in Ocala Fl 34477. Im at stage one.

  2. Marie NICHOLS says:

    I would like to participate in study. My dad, his mom and his twin sister all had Parkinson’s. My grandma lived pretty well with Disease for 20 years. My dad’s twin sister had Lewey Body disease, she did not fair well at all. My dad diagnosed late because repeatedly refused treatment as he would not even see a neurologist until I finally got very firm with him. He recently passed away at age 77. He also had significant heart disease. I read as much as I can on Parkinson’s.
    Thanks,
    Marie RN

  3. eduardo says:

    Hello my name is Eduardo Marin i live in a Palm Beach Florida i got Parkinson since 2015 i like to help with the vaccine im avaiable anytime thank you

Leave a Comment

Your email address will not be published. Required fields are marked *